Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Authors: Gebremariam, Teclegiorgis; Alkhazraji, Sondus; Alqarihi, Abdullah; Wiederhold, Nathan P.; Shaw, Karen Joy; Patterson, Thomas F.; Filler, Scott G.; Ibrahim, Ashraf S.
Abstract
Mucormycosis is a life-threatening infection with high mortality that occurs predominantly in immunocompromised patients. Manogepix (MGX) is a novel antifungal that targets Gwt1, a protein involved in an early step in the conserved glycosylphosphotidyl inositol (GPI) posttranslational modification pathway of surface proteins in eukaryotic cells. Inhibition of fungal inositol acylation by MGX results in pleiotropic effects, including inhibition of maturation of GPI-anchored proteins necessary for growth and virulence. MGX has been previously shown to have in vitro activity against some strains of Mucorales. Here, we assessed the in vivo activity of the prodrug fosmanogepix, currently in clinical development for the treatment of invasive fungal infections, against two Rhizopus arrhizus strains with high (4.0 mu g/ml) and low (0.25 mu g/ml) minimum effective concentration (MEC) values. In both invasive pulmonary infection models, treatment of mice with 78 mg/kg or 104 mg/kg fosmanogepix, along with 1-aminobenzotriazole to enhance the serum half-life of MGX in mice, significantly increased median survival time and prolonged overall survival by day 21 postinfection compared to placebo. In addition, administration of fosmanogepix resulted in a 1 to 2 log reduction in both lung and brain fungal burden. For the 104 mg/kg fosmanogepix dose, tissue clearance and survival were comparable to clinically relevant doses of isavuconazole (ISA), which is FDA approved for the treatment of mucormycosis. These results support continued development of fosmanogepix as a first-in-class treatment for invasive mucormycosis.
Characterization of the variable merozoite surface antigen (VMSA) gene family ofBabesia orientalis
PARASITOLOGY RESEARCH
Authors: Nie, Zheng; Xia, Yingjun; Yu, Long; Li, Muxiao; Guo, Jiaying; Sun, Yali; Ao, Yangsiqi; Zhan, Xueyan; Zhao, Yangnan; An, Xiaomeng; Liu, Qin; Sen, Wang; Shu, Xiang; Li, Dongfang; He, Lan; Zhao, Junlong
Abstract
Due to its wide presence in apicomplexan parasites as well as high polymorphism and antigenic diversity, the variable merozoite surface antigen (VMSA) family inBabesiasp. has attracted increasing attention of researchers. Here, all the reported VMSA genesof Babesia spp.were obtained from GenBank, and multiple alignments were performed by using conserved regions to blast theBabesia orientalisgenome database (unpublished data). Five MSA genes (namedMSA-2a1,MSA-2a2,MSA-2c1,MSA-1, andMSA-2c2, respectively) were identified, sequenced, and cloned fromB. orientalis, which were shown to encode proteins with open reading frames ranging in size from 266 (MSA-2c1) to 317 (MSA-1) amino acids. All the five proteins contain an MSA-2c superfamily conserved domain, with an identical signal peptide and glycosyl phosphatidyl inositol (GPI)-anchor for each of them. The five proteins were also predicted to contain B cell epitopes, with only three for BoMSA-2c1, the smallest protein in the BoVMSA family, while at least six for each of the others. Notably, BoMSA-2a1 has 2 identical copies, a specific phenomenon only present inB. orientalis. This research has determined the MSA genes ofB. orientalisand provides a genetic basis for further research of functional genes inB. orientalis.